2022 American Transplant Congress

TOPIC: Clinical Science » Kidney » 45 - Kidney Chronic Antibody Mediated Rejection

Predictors of Response to Belatacept Conversion in Kidney Transplant Patients with Chronic Active Antibody-Mediated Rejection
D. Kumar¹, R. Winstead¹, H. Iftikhar¹, R. Minniti¹, S. Khorsandi¹, J. Christensen¹, I. Yakubu¹, I. Moinuddin¹, L. Kamal¹, P. Halloran², G. Gupta¹
The Natural History of De Novo DSA After Kidney Transplantation
C. López del Moral¹, N. Lachmann², S. Hergovits², D. Stauch², A. Akifova³, M. Naik³, B. Osmanodja³, D. Schmidt³, K. Budde³
Three-Way Comparison of Central DSA, %dd-cf DNA, and Molecular Biopsy Findings in the Trifecta Study
P. F. Halloran¹, L. G. Hidalgo², Z. Demko³, A. Prewett³, J. Reeve¹, C. Lawrence⁴, D. Lowe⁴, P. Billings³, .. and the Trifecta Investigators⁵
Tocilizumab in Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients: A Case Series
B. Boonpheng¹, R. Bakthavatsalam², C. D. Blosser¹, I. C. De Castro¹, I. Gimferrer³, Y. Ng¹, N. Leca¹
Which is More Important for Predicting De Novo DSA Production, B Cell Epitope (EPLET) or T Cell Epitope (PIRCHE) Analysis ?
T. Kobayashi¹, T. Tomosugi², S. Sakamoto², S. Ashimine¹, K. Iwasaki¹, M. Niemann³, E. Spierings⁴, Y. Miwa¹, M. Okumura¹, K. Ishiyama¹, A. Takeda², N. Goto², S. Narumi², Y. Watarai²